 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
5 News |  |
- ||| encaleret (BBP-305) / BridgeBio
Trial primary completion date: CALIBRATE: Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (clinicaltrials.gov) - May 14, 2024
P3, N=60, Recruiting, Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company
Trial primary completion date: Jun 2024 --> Apr 2025
- ||| encaleret (BBP-305) / BridgeBio
Trial completion date, Trial primary completion date: CALIBRATE: Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (clinicaltrials.gov) - Sep 6, 2023
P3, N=60, Recruiting, Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company
Trial primary completion date: Jun 2024 --> Apr 2025 Trial completion date: Dec 2028 --> Sep 2028 | Trial primary completion date: Dec 2023 --> Jun 2024
- ||||| encaleret (BBP-305) / BridgeBio
Enrollment change: CALIBRATE: Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (clinicaltrials.gov) - Apr 26, 2023
P3, N=60, Recruiting, Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company
Trial completion date: Dec 2028 --> Sep 2028 | Trial primary completion date: Dec 2023 --> Jun 2024 N=45 --> 60
- |||| encaleret (BBP-305) / BridgeBio
New P3 trial: CALIBRATE: Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (clinicaltrials.gov) - Jan 11, 2023
P3, N=45, Recruiting, Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company
- | Oxarol (maxacalcitol) / Roche, Edirol (eldecalcitol) / Roche, Taisho, Fulstan (falecalcitriol) / Kissei, Sumitomo Dainippon
Journal: Active vitamin D and vitamin D analogs stimulate fibroblast growth factor 23 production in osteocyte-like cells via the vitamin D receptor. (Pubmed Central) - Dec 18, 2020
Therefore, the induction of FGF23 in osteocytes by vitamin D may be primarily mediated via VDR. The potential of 25(OH)vitamin D, paricalcitol, and maxacalcitol to induce FGF23 production was almost the same as that of 1α,25-dihydroxyvitamin D. However, falecalcitriol and eldecalcitol demonstrated a reduced potential to induce FGF23 compared with 1α,25-dihydroxyvitamin D. Our results demonstrate that FGF23 induction is different among the analogs of 1α,25-dihydroxyvitamin D. Therefore, an appropriate vitamin D analog should be chosen for each patient with mineral and bone disorder, considering its effect on FGF23 production.